Related Experiment Video

Updated: Nov 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K

Blocking the Enablers: Selective Inhibition of CDK9 Reins in an Unchecked Master Regulator

Aseem Z Ansari1

  • 1Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Cell Chemical Biology
|February 19, 2021
PubMed

Insights

Researchers identified a selective inhibitor targeting a transcriptional kinase crucial for full-length mRNA synthesis. This discovery offers a new strategy for castration-resistant prostate cancer by curbing tumor growth through transcription therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) variants.
  • Targeting AR signaling is a key strategy, but resistance mechanisms emerge.
  • Novel therapeutic targets are needed to overcome treatment resistance.

Purpose of the Study:

  • To identify and characterize novel therapeutic targets for CRPC.
  • To investigate the role of a specific transcriptional kinase in AR variant-driven prostate cancer.
  • To evaluate a selective inhibitor of this kinase as a potential treatment for CRPC.

Main Methods:

  • Utilized a combination of molecular biology techniques to study AR variant function.
  • Developed and tested a selective inhibitor targeting a key transcriptional kinase.
  • Assessed the impact of the inhibitor on mRNA synthesis and tumor growth in preclinical models.

Main Results:

  • Identified a transcriptional kinase essential for full-length mRNA synthesis.
  • Demonstrated that inhibiting this kinase effectively curbs tumor growth in CRPC models.
  • The selective inhibitor showed promise in disabling AR variant-driven cancer.

Conclusions:

  • A selective inhibitor of a transcriptional kinase represents a promising new therapeutic strategy for CRPC.
  • Targeting this kinase offers a novel approach for transcription therapy in prostate cancer.
  • Further development of this inhibitor could lead to improved treatments for patients with advanced prostate cancer.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.1K
A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.1K
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
118.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.4K